Akshya Vasudev1, Salimah Z Shariff2, Kuan Liu2, Amer M Burhan3, Nathan Herrmann4, Sean Leonard2, Muhammad Mamdani5. 1. Division of Geriatric Psychiatry, Department of Psychiatry, Western University, London, Canada; Division of Clinical Pharmacology, Department of Medicine, Western University, London, Canada. Electronic address: akshya.vasudev@uwo.ca. 2. Institute for Clinical Evaluative Sciences, London, Canada. 3. Division of Geriatric Psychiatry, Department of Psychiatry, Western University, London, Canada. 4. Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. 5. Institute for Clinical Evaluative Sciences, London, Canada; Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Canada; Institute of Health Policy, Management, and Evaluation, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
Abstract
OBJECTIVE: Guidelines worldwide have cautioned against the use of antipsychotics as first-line agents to treat neuropsychiatric symptoms of dementia. We aimed to investigate the changes over time in the dispensing of antipsychotics and other psychotropics among older adults with dementia living in long-term care facilities. METHODS: We used drug claims data from Ontario, Canada, to calculate quarterly rates of prescription dispensing of six psychotropic drug classes among all elderly (≥65 years of age) long-term care residents with dementia from January 1, 2004, to March 31, 2013. Psychotropic drugs were classified into the following categories: atypical and conventional antipsychotics, non-sedative and sedative antidepressants, anti-epileptics, and benzodiazepines. We used time-series analysis to assess trends over time. RESULTS: The study sample increased by 21% over the 10-year study period, from 49,251 patients to 59,785 patients. The majority of patients (within the range of 75%-79%) were dispensed at least one psychotropic medication. At the beginning of the study period atypical antipsychotics (38%) were the most frequently dispensed psychotropic, followed by benzodiazepines (28%), non-sedative antidepressants (27%), sedative antidepressants (17%), anti-epileptics (7%), and conventional antipsychotics (3%). Dispensing of anti-epileptics (2% increase) and conventional antipsychotics (1% decrease) displayed modest changes over time, but we observed more pronounced changes in dispensing of benzodiazepines (11% decrease) and atypical antipsychotics (4% decrease). Concurrently, we observed a substantial growth in the dispensing of both sedative (15% increase) and non-sedative (9% increase) antidepressants. The proportion of patients dispensed two or more psychotropic drug classes increased from 42% in 2004 to 50% in 2013. CONCLUSIONS: Utilization patterns of psychotropic drugs in institutionalized patients with dementia have changed over the past decade. Although their use declined slightly over the study period, atypical antipsychotics continue to be used at a high rate. A decline in the use of benzodiazepines along with an increased use of sedative and non-sedative antidepressants suggests that the latter class of drugs is being substituted for the former in the management of neuropsychiatric symptoms. Psychotropic polypharmacy continues to be highly prevalent in these patient samples.
OBJECTIVE: Guidelines worldwide have cautioned against the use of antipsychotics as first-line agents to treat neuropsychiatric symptoms of dementia. We aimed to investigate the changes over time in the dispensing of antipsychotics and other psychotropics among older adults with dementia living in long-term care facilities. METHODS: We used drug claims data from Ontario, Canada, to calculate quarterly rates of prescription dispensing of six psychotropic drug classes among all elderly (≥65 years of age) long-term care residents with dementia from January 1, 2004, to March 31, 2013. Psychotropic drugs were classified into the following categories: atypical and conventional antipsychotics, non-sedative and sedative antidepressants, anti-epileptics, and benzodiazepines. We used time-series analysis to assess trends over time. RESULTS: The study sample increased by 21% over the 10-year study period, from 49,251 patients to 59,785 patients. The majority of patients (within the range of 75%-79%) were dispensed at least one psychotropic medication. At the beginning of the study period atypical antipsychotics (38%) were the most frequently dispensed psychotropic, followed by benzodiazepines (28%), non-sedative antidepressants (27%), sedative antidepressants (17%), anti-epileptics (7%), and conventional antipsychotics (3%). Dispensing of anti-epileptics (2% increase) and conventional antipsychotics (1% decrease) displayed modest changes over time, but we observed more pronounced changes in dispensing of benzodiazepines (11% decrease) and atypical antipsychotics (4% decrease). Concurrently, we observed a substantial growth in the dispensing of both sedative (15% increase) and non-sedative (9% increase) antidepressants. The proportion of patients dispensed two or more psychotropic drug classes increased from 42% in 2004 to 50% in 2013. CONCLUSIONS: Utilization patterns of psychotropic drugs in institutionalized patients with dementia have changed over the past decade. Although their use declined slightly over the study period, atypical antipsychotics continue to be used at a high rate. A decline in the use of benzodiazepines along with an increased use of sedative and non-sedative antidepressants suggests that the latter class of drugs is being substituted for the former in the management of neuropsychiatric symptoms. Psychotropic polypharmacy continues to be highly prevalent in these patient samples.
Authors: Jennifer A Watt; Tara Gomes; Susan E Bronskill; Anjie Huang; Peter C Austin; Joanne M Ho; Sharon E Straus Journal: CMAJ Date: 2018-11-26 Impact factor: 8.262
Authors: Jonathan Brett; Benjamin Daniels; Emily A Karanges; Nicholas A Buckley; Carl Schneider; Atheer Nassir; Andrew J McLachlan; Sallie-Anne Pearson Journal: Br J Clin Pharmacol Date: 2017-08-16 Impact factor: 4.335
Authors: Lauren B Gerlach; Helen C Kales; Hyungjin Myra Kim; Julie P W Bynum; Claire Chiang; Julie Strominger; Donovan T Maust Journal: J Am Med Dir Assoc Date: 2020-07-18 Impact factor: 4.669
Authors: Donovan T Maust; Julie Strominger; H Myra Kim; Kenneth M Langa; Julie P W Bynum; Chiang-Hua Chang; Helen C Kales; Kara Zivin; Erica Solway; Steven C Marcus Journal: JAMA Date: 2021-03-09 Impact factor: 56.272